Opening up malaria drug discovery for good
Scientists are exploring new open innovation and open source approaches to catalyze malaria drug development and move us closer to achieving the goal of ending malaria for good.
Sign up to receive news and updates from GHTC.
Scientists are exploring new open innovation and open source approaches to catalyze malaria drug development and move us closer to achieving the goal of ending malaria for good.
GHTC member the Drugs for Neglected Diseases initiative will test an affordable hepatitis C regimen in Malaysia and Thailand, with a guarantee from generic drug manufacturer Pharco Pharmaceuticals that, if successful, the product will be priced at no more than US$294 for the entire regimen.
Valentine’s Day seems like a fitting occasion to shine some needed light on a disease that can begin with a late-night “kiss” but ends with a broken heart.
In this guest post, Dr. Mel Spigelman—president and CEO of the TB Alliance—writes about advancing the first-ever drug regimen designed to treat both drug-sensitive and some forms of multi-drug resistant tuberculosis (TB) to a global Phase III clinical